학술논문
Impact of Early Switching to Nilotinib As Second Line TKI in Patients with Chronic Myeloid Leukemia Who Were Intolerant to, Suboptimal to and Failed Imatinib: The Thai Multi-Centered Study
Document Type
Abstract
Author
Source
In Blood 29 November 2018 132 Supplement 1:4267-4267
Subject
Language
ISSN
0006-4971